PD-1 blockade induces responses by inhibiting adaptive immune resistance
Explore this paper's citation graph
Summary
It is shown that pre-existing CD8+ T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy.
- Type
- article
- Published
- 2014-11-26
- Cited by
- 6,198
- References
- 21
- Access
- Open access
- OpenAlex
- https://openalex.org/W2039123767
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:1804354
Keywords
Immune system, PD-L1, CD8, Blockade, Antigen
References
- Effector memory T cells, early metastasis, and survival in colorectal cancer.
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
- Abstract 633: Inhibition of TGFβ as a strategy to convert the irradiated tumor into in situ individualized vaccine
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
- Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.
- The blockade of immune checkpoints in cancer immunotherapy
- Using synthetic templates to design an unbiased multiplex PCR assay
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
- Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients
- Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T Cell Rejection Function in Tumors
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
Cited by
- New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer.
- Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12
- Differential immune microenvironments and response to immune checkpoint blockade amongst molecular subtypes of murine medulloblastoma
- CTLA-4 and PD-1 Pathways
- Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome
- Cancer immune contexture and immunotherapy.
- Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas
- The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma
- Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies
- Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein–Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines
- Transcriptional mechanisms of resistance to anti-PD-1 therapy
- Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases
- Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- Development of pH-sensitive Dextran Derivatives with Strong Adjuvant Function and Their Application to Antigen Delivery
- Prognostic value of tumor PD‐L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer
- From Famine to Feast: Developing Early Phase Combination Immunotherapy Trials Wisely
- Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
- Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.
Related papers
- PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination.
- Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
- Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence
- PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
- The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
- Detailed characterization of PD-1/PD-L1 and CTLA4 expression and tumor-infiltrating lymphocytes in yolk sac tumors
- Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
- Detailed characterization of PD-1/PD-L1 and CTLA4 expression and tumor-infiltrating lymphocytes in yolk sac tumors.